LillyDirect and Walmart launch the first retail pickup at direct-to-consumer prices

Eli Lilly and Walmart said on Oct. 29 that patients buying Zepbound (tirzepatide) single-dose vials through LillyDirect will be able to pick them up at Walmart pharmacies nationwide by mid-November, at the same self-pay prices Lilly charges for home delivery ^[1]. It is the first time LillyDirect's direct-to-consumer pricing has been offered at a retail pharmacy counter ^[1].

The prices are $349 per month for the 2.5 mg recommended starting dose and $499 per month for all other doses — 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg ^[1]. Lilly says the $499 price for doses above 5 mg requires patients to meet the requirements of the Zepbound Self Pay Journey Program, which the company describes as designed to support continuity of care and access and which is subject to terms and conditions ^[1]. The prices are the same whether a patient chooses free home delivery from LillyDirect or pickup at Walmart ^[1].

How the pickup works

According to Lilly, prescriptions are routed directly to LillyDirect Self Pay Pharmacy Solutions from a health care provider's electronic health record system ^[1]. At checkout, the patient chooses either home delivery or local pickup at a Walmart pharmacy ^[1]. Walmart operates nearly 4,600 pharmacies in the U.S. and employs more than 50,000 pharmacists and pharmacy technicians, the companies said ^[1].

The self-pay prices apply to anyone with a valid, on-label Zepbound prescription, regardless of insurance status, and patients access the vials without going through insurance ^[1]. Lilly says its direct-to-consumer pricing represents a discount of 50% or more compared with the list price of other incretin (GLP-1) medicines for obesity ^[1]. The press release does not name those comparison products or give their list prices, so the exact size of the gap for any specific competing drug is not spelled out in the source.

Lilly also disclosed a figure that shows how much of its obesity business has shifted away from traditional pharmacy channels: in the second quarter of 2025, roughly 35% of new Zepbound prescriptions were filled through LillyDirect ^[1]. "The growth of LillyDirect's direct-to-consumer offering underscores the momentum behind a more modern, consumer-driven model of care," said Jennifer Mazur, senior vice president and general manager of LillyDirect ^[1].

Why it matters for patients

For people paying cash, the main change here is logistics, not price. The cost is identical either way ^[1], so the practical difference is whether a vial arrives by mail or waits at a local counter. That may matter for people who travel, who have had packages go missing, or who want to talk with a pharmacist in person — Walmart's pharmacy chief, Kevin Host, framed the collaboration around those in-store relationships ^[1].

It also matters that this program covers single-dose vials, not the autoinjector pens, and that it runs outside insurance ^[1]. Money spent through a cash-pay channel typically works differently from money spent under a health plan, but the announcement does not address deductibles, out-of-pocket maximums, or how these purchases interact with insurance benefits, so that is not settled by this source.

The tiered pricing is worth reading closely. The $349 figure applies only to the 2.5 mg starting dose ^[1]. Most people who continue on tirzepatide move to higher strengths, where the price is $499 per month and, per Lilly, conditional on meeting the Self Pay Journey Program's requirements ^[1]. The release does not detail what those requirements are.

Zepbound is approved for adults with obesity, or some adults with overweight who also have weight-related medical problems, and for adults with moderate-to-severe obstructive sleep apnea and obesity, and it is meant to be used with a reduced-calorie diet and increased physical activity ^[1]. Lilly notes it should not be used with other tirzepatide products or any GLP-1 receptor agonist, and that it is not known whether it is safe and effective in children ^[1]. The label carries a warning about thyroid tumors, including medullary thyroid carcinoma, and lists risks including severe stomach problems, dehydration and kidney problems, gallbladder problems, pancreatitis, serious allergic reactions, low blood sugar, and vision changes in patients with type 2 diabetes ^[1].

What happens next

Lilly says Zepbound vials will be available for pickup at Walmart pharmacies nationwide by mid-November 2025 ^[1]. The company added that it will "continue to explore additional options to broaden patient access," without naming other retailers or dates ^[1]. Whether other manufacturers follow with similar retail cash-pay arrangements is not addressed in the announcement.